3 Growth Stocks the Market Is Throwing Away and Why You Should Pick Them Up

The article argues that ServiceNow, Roblox, and Boston Scientific have been overly sold off despite underlying fundamentals, with ServiceNow posting 19% Q1 revenue growth and 21% growth in next-12-month remaining performance obligations to $12.6 billion. Roblox’s 2026 guidance was cut to 20%-25% growth from 23%-29% as age-verification checks slow onboarding, while Boston Scientific reduced 2026 revenue growth guidance to 6.5%-8% from 10%-11%. The overall tone is constructive on all three names, especially Boston Scientific where analysts still see about 50% upside to the $85.84 consensus target.

Analysis

The market is conflating three very different situations: a quality software platform de-rated with the AI cohort, a product transition that depresses near-term usage but improves the franchise, and a med-tech name where expectations have simply come in too far. ServiceNow is the cleanest dislocation because the selloff is not tied to a broken business model; it is tied to multiple compression in the entire enterprise software stack. That creates a second-order opportunity: if IT spending stabilizes, NOW should re-rate faster than lower-quality AI software names because its revenue base is already monetized and its backlog provides a visibility cushion.

Roblox is more nuanced. The age-verification drag is a classic example of a compliance cost that hurts growth optics before it helps unit economics. Near term, the real risk is not just slower bookings; it is that the market extrapolates weaker engagement into a broader ceiling on monetization, which can keep the stock impaired for months. But if safety friction reduces attrition among parents and younger cohorts, Roblox may exit this period with a more durable user graph and better long-run advertiser/creator confidence than peers that remain less regulated.

Boston Scientific looks like a guidance-reset story rather than an operating deterioration story. The key contrarian point is that the market is punishing one implant franchise while underweighting the breadth of the company’s growth engine and the likelihood that multiple expansion returns once the Watchman debate stops dominating headlines. In med-tech, sentiment usually overshoots on binary clinical narratives, and that creates a setup where a few quarters of execution can drive a sharp catch-up rally.

Key Decisions for Investors

• Go long NOW on a 3-6 month horizon; the setup is a de-rating reversal trade with asymmetric upside if enterprise software multiples normalize. Risk: if AI sentiment deteriorates further, this can remain cheap longer than expected.
• Buy BSX into weakness for a 6-12 month mean-reversion trade; pair against a lower-quality med-tech or device basket if available. Reward improves materially if management proves the revised guide is conservative.
• Treat RBLX as a 6-18 month optionality name, not a momentum trade; accumulate only on post-guidance weakness or via call spreads to limit downside. The thesis is that compliance friction is front-loaded while trust-based monetization is back-end loaded.
• Avoid shorting SOUNW as a basket proxy for AI software from here unless you can explicitly separate it from profitable platform software like NOW. The market may still punish the cohort, but the risk/reward is worse in the higher-quality names that can self-fund growth.
• Consider a pair: long NOW / short a more speculative AI software peer over the next 1-2 quarters. This isolates the valuation reset in AI software while favoring the business with better recurring revenue quality and backlog visibility.